Form 4: Akoya Biosciences Chief Clinical Officer Reports Share and Option Dispositions Following Quanterix Merger Completion
Officer Transaction Report (Merger Related)
Akoya Biosciences' Chief Clinical Officer, Pascal Bamford, reported the disposition of common stock and termination of stock options and conversion of restricted stock units as a result of the company's merger with Quanterix Corporation on July 8, 2025.
Summary
- Pascal Bamford, Chief Clinical Officer of Akoya Biosciences, Inc., reported changes in his beneficial ownership due to the merger of Akoya Biosciences with Quanterix Corporation.
- On July 8, 2025, Akoya Biosciences became a wholly-owned subsidiary of Quanterix Corporation.
- Each outstanding share of Akoya common stock was converted into the right to receive 0.1461 shares of Quanterix common stock and $0.38 in cash.
- Mr. Bamford disposed of 9,488 and 196,250 shares of Akoya common stock, which were converted into the merger consideration.
- Aggregate unvested restricted stock units (RSUs) totaling 196,250 shares were converted into the right to receive the merger consideration upon vesting, subject to original terms.
- All outstanding employee stock options to purchase Akoya common stock were accelerated. Options with an exercise price equal to or greater than the Per Share Merger Consideration were terminated and cancelled for no consideration.
- Mr. Bamford's options for 150,000 shares (exercise price $13.34), 25,000 shares (exercise price $12.3), 15,000 shares (exercise price $5.96), and 50,000 shares (exercise price $5.35) were terminated.
- Following these transactions, Mr. Bamford beneficially owns 0 shares of Akoya common stock and 0 derivative securities of Akoya.
Sentiment
Score: 7
Explanation: The filing reports the expected outcome of a merger, which is a significant corporate event. While some options were terminated for no consideration, the overall transaction provides liquidity and a new structure for shareholders and equity holders. The factual reporting of a pre-planned event generally carries a neutral-to-positive sentiment as it signifies the successful completion of a strategic initiative.
Positives
- Completion of the merger provides liquidity and a new ownership structure for Akoya shareholders.
- Unvested restricted stock units (RSUs) were converted into the right to receive the merger consideration upon vesting, preserving their value for the holder.
Negatives
- Employee stock options with exercise prices equal to or greater than the merger consideration were terminated for no consideration, resulting in a loss of potential value for the option holder. This includes options for 150,000 shares (exercise price $13.34), 25,000 shares (exercise price $12.3), 15,000 shares (exercise price $5.96), and 50,000 shares (exercise price $5.35).
Risks
- The Per Share Stock Consideration and Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement, introducing uncertainty regarding the final value received.
Future Outlook
The unvested restricted stock units (RSUs) of Akoya Biosciences were converted into the right to receive the Per Share Merger Consideration upon their original vesting schedule, indicating future receipt of value for these equity awards.
Management Comments
- No direct quotes or paraphrased statements from management are provided.
Industry Context
This filing reflects a significant consolidation event within the biotechnology or life sciences sector, specifically involving companies focused on advanced analytical instruments or diagnostics, as Akoya Biosciences (spatial biology) is acquired by Quanterix Corporation (ultra-sensitive immunoassay detection). Such mergers are common for strategic growth, market expansion, or technology integration.
Comparison to Industry Standards
- NA
Legal Proceedings
- No legal proceedings or regulatory matters are mentioned.
Related Party Transactions
- No related party dealings are disclosed beyond the merger itself, which is a corporate transaction.
Stakeholder Impact
- Shareholders: Akoya Biosciences shareholders received a combination of Quanterix common stock and cash for their shares, effectively converting their investment into a stake in Quanterix and cash proceeds.
- Employees (with equity): Employees holding unvested restricted stock units (RSUs) will receive merger consideration upon vesting, while those with out-of-the-money stock options saw their options terminated for no value.
Next Steps
- Continued vesting of Rollover RSUs, leading to the receipt of Per Share Merger Consideration.
Key Dates
| Date | Description |
|---|---|
| 2025-04-28 | Date of the Amended and Restated Agreement and Plan of Merger. |
| 2025-07-08 | Closing Date of the merger between Akoya Biosciences and Quanterix Corporation, and the date of the reported transactions. |
| 2025-07-10 | Signature date of the Form 4 filing by Pascal Bamford. |
| 2031-11-12 | Expiration date of a terminated employee stock option. |
| 2033-02-23 | Expiration date of a terminated employee stock option. |
| 2033-05-18 | Expiration date of a terminated employee stock option. |
| 2034-02-22 | Expiration date of a terminated employee stock option. |
Keywords
Akoya Biosciences, Quanterix Corporation, Merger, SEC Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, Corporate Acquisition, Biotechnology, Life Sciences, Pascal Bamford
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.